<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-05T17:22:46Z</responseDate><request verb="GetRecord" identifier="oai:riuma.uma.es:10630/30295" metadataPrefix="oai_dc">https://riuma.uma.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:riuma.uma.es:10630/30295</identifier><datestamp>2026-02-03T10:52:22Z</datestamp><setSpec>com_10630_2254</setSpec><setSpec>col_10630_37953</setSpec></header><metadata><oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain</dc:title>
   <dc:creator>Maravilla-Herrera, Paulina</dc:creator>
   <dc:creator>Merino, Maria</dc:creator>
   <dc:creator>Alfonso Zamora, Santiago</dc:creator>
   <dc:creator>Balea Filgueiras, Jesús</dc:creator>
   <dc:creator>Carrascosa Carrillo, José Manuel</dc:creator>
   <dc:creator>Delgado Sánchez, Olga</dc:creator>
   <dc:creator>Dolz Sinisterra, Francisco</dc:creator>
   <dc:creator>García-Ruiz, Antonio J.</dc:creator>
   <dc:creator>Herranz Pinto, Pedro</dc:creator>
   <dc:creator>Manfredi, Antonio</dc:creator>
   <dc:creator>Martínez Olmos, José</dc:creator>
   <dc:creator>Morales de los Ríos Luna, Paloma</dc:creator>
   <dc:creator>Puig, Lluís</dc:creator>
   <dc:creator>Ros, Sandra</dc:creator>
   <dc:creator>Hidalgo-Vega, Álvaro</dc:creator>
   <dc:subject>Psoriasis - Tratamiento</dc:subject>
   <dc:subject>Psoriasis - Aspectos sociales</dc:subject>
   <dc:subject>Social return</dc:subject>
   <dc:subject>Socioeconomic impact</dc:subject>
   <dc:subject>Psoriasis</dc:subject>
   <dc:subject>Quality of life</dc:subject>
   <dc:subject>Out-of-pocket (OOP) expenses</dc:subject>
   <dc:subject>Activities of daily living</dc:subject>
   <dc:description>Therapeutic advances have made PASI 90 or PASI 100 responses possible in most patients treated with some biologics. A greater response may generate social value beyond clinical outcomes that would benefit both patients and society.&#xd;
Methods: A 1-year economic model was applied to estimate the impact of having a PASI 75, PASI 90, or PASI 100 response in four areas of analysis (quality of life, activities of daily living, work productivity, and out-of-pocket expenditures) and the social value of having a PASI 90 or PASI 100 response in comparison with a PASI 75 response. A mixed-methods approach based on the scientific literature, a focus group with patient, and an advisory committee with psoriasis stakeholders was used. The model included three diferent scenarios: having a PASI 90 vs a PASI 75 response; a PASI 100 vs a PASI 90 response; and a PASI 100 vs a PASI 75 response. A sensitivity analysis was included.&#xd;
Results: The annual economic impact per patient with moderate-to-severe plaque psoriasis having a PASI 75 response was estimated at Ł 6,139, mainly related to labour productivity losses and quality of life reductions. Having a PASI 90 or a PASI 100 response would reduce this impact to e3,956 or e1,353, respectively. Accordingly, the social value of having a PASI 90 instead of a PASI 75 response was estimated at e2,183, and e4,786 with a PASI 100 response.&#xd;
Discussion: A PASI 90 or PASI 100 response would have a lower economic impact and a greater social value than a PASI 75 response for patients with moderate-to-severe plaque psoriasis.</dc:description>
   <dc:date>2024-02-09T12:15:02Z</dc:date>
   <dc:date>2024-02-09T12:15:02Z</dc:date>
   <dc:date>2023</dc:date>
   <dc:type>journal article</dc:type>
   <dc:type>VoR</dc:type>
   <dc:identifier>Maravilla-Herrera P, Merino M, Alfonso Zamora S, Balea Filgueiras J, Carrascosa Carrillo JM, Delgado Sánchez O, Dolz Sinisterra F, García-Ruiz A, Herranz Pinto P, Manfredi A, Martínez Olmos J, Morales de los Ríos Luna P, Puig L, Ros S and Hidalgo-Vega Á (2023) The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain. Front. Public Health 11. doi:10.3389/fpubh.2023.1000776</dc:identifier>
   <dc:identifier>https://hdl.handle.net/10630/30295</dc:identifier>
   <dc:identifier>10.3389/fpubh.2023.1000776</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:rights>Attribution 4.0 Internacional</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
   <dc:rights>open access</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>Hai Fang, Peking University, China</dc:publisher>
</oai_dc:dc>
</metadata></record></GetRecord></OAI-PMH>